GlassScriptPhysician profile
Nick Steinauer
NPI 1740255157
$1,237.92
in general payments reported to CMS, 2019-2025
23 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $34.81 · 2021: $34.33 · 2024: $421 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.23 | 2024 | Xifaxan |
| Astellas Pharma US INC | $143.83 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $140.76 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $108.82 | 2024-2025 | Myfembree |
| Boston Scientific Corporation | $102.37 | 2019 | |
| Biogen, INC. | $90.97 | 2024-2025 | Zurzuvae |
| Karl Storz Endoscopy-America | $60.52 | 2019-2021 | |
| Abbvie INC. | $55.88 | 2019-2020 | |
| Pfizer INC. | $54.14 | 2019-2021 | |
| Organon LLC | $39.26 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.31 | 2024-2025 | |
| Coopersurgical, INC. | $31.87 | 2025 | Paragard T 380a, Endosee |
| Octapharma USA, INC. | $26.40 | 2025 | Fibryga |
| Pelvital USA, INC. | $19.87 | 2025 | |
| Lilly USA, LLC | $19.32 | 2025 | Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $16.65 | 2025 | Zynrelef |
| Duchesnay USA Incorporated | $14.33 | 2019 | |
| Novo Nordisk INC | $13.67 | 2025 | Rybelsus, Ozempic |
| Allergan, INC. | $13.22 | 2019 | |
| Therapeuticsmd, INC. | $12.24 | 2019 | |
| Olympus America INC. | $11.70 | 2019 | |
| Daiichi Sankyo INC. | $11.60 | 2019 | |
| Davol INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Steinauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.